Epigenetic Regulation of p21cip1/waf1 in Human Cancer by Ocker, Matthias et al.
cancers
Review
Epigenetic Regulation of p21cip1/waf1 in Human Cancer
Matthias Ocker 1,2 , Samar Al Bitar 3, Ana Carolina Monteiro 4, Hala Gali-Muhtasib 3,5 and
Regine Schneider-Stock 4,6,*
1 Bayer AG, Translational Medicine Oncology, 13353 Berlin, Germany
2 Department of Gastroenterology, CBF, Charité University Medicine Berlin, 10117 Berlin, Germany
3 Department of Biology, American University of Beirut, Beirut 110236, Lebanon
4 Experimental Tumor Pathology, Institute of Pathology, University Hospital, Friedrich-Alexander University
Erlangen-Nuremberg, 91054 Erlangen, Germany
5 Center for Drug Discovery, American University of Beirut, Beirut 110236, Lebanon
6 Experimental Tumor Pathology, FAU Erlangen-Nuremberg, Universitaetsstrasse 22,
91054 Erlangen, Germany
* Correspondence: regine.schneider-stock@uk-erlangen.de
Received: 3 July 2019; Accepted: 3 September 2019; Published: 11 September 2019


Abstract: p21cip1/waf1 is a central regulator of cell cycle control and survival. While mutations are rare,
it is commonly dysregulated in several human cancers due to epigenetic mechanisms influencing its
transcriptional control. These mechanisms include promoter hypermethylation as well as additional
pathways such as histone acetylation or methylation. The epigenetic regulators include writers,
such as DNA methyltransferases (DNMTs); histone acetyltransferases (HATs) and histone lysine
methyltransferases; erasers, such as histone deacetylases (HDACs); histone lysine demethylases [e.g.,
the Lysine Demethylase (KDM) family]; DNA hydroxylases; readers, such as the methyl-CpG-binding
proteins (MBPs); and bromodomain-containing proteins, including the bromo- and extraterminal
domain (BET) family. We further discuss the roles that long noncoding RNAs (lncRNAs) and
microRNAs (miRNAs) play in the epigenetic control of p21cip1/waf1 expression and its function in
human cancers.
Keywords: p21cip1/waf1; DNA methylation; histone acetylation; histone methylation; lncRNA; miRNA;
epigenetic reader; epigenetic writer; epigenetic eraser
1. Introduction
Regulation of gene function is essential to the coordination of cellular processes and tissue
homeostasis. In cancer, dysregulation of genes is commonly mediated by genetic events such as
activating mutations (e.g., k-RAS, PI3K, EGFR), gene fusions (e.g., BCR-ABL, NTREK), or amplifications
(e.g., FGFR). Besides these mechanisms, additional features “on top” of the genetic information,
i.e., epigenetic modifications, are heavily involved in the orchestration of gene functions. The term
‘epigenetics’ was first used by Conrad Hal Waddington in 1942 and is now defined as inherited changes
in gene expression without alterations in the DNA [1,2]. While Hanahan and Weinberg defined the
hallmarks of cancer based largely on genetic alterations, an increasing body of evidence now supports
the view that epigenetic mechanisms contribute to the development of the malignant phenotype and
can even drive cancer formation on their own [3,4].
An epigenetic signature is mediated by enzymes that alter DNA methylation or modifications
of histones via methylation, acetylation, phosphorylation, ubiquitination, and various other
mechanisms [5]. Besides these so-called epigenetic writers and erasers, enzymes that “read” the
chromatin state form part of the epigenetic machinery [6]. Furthermore, various noncoding RNAs
have recently been identified as playing a major role in epigenetic regulation [7].
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p21cip1/waf1 is a low-molecular-weight molecule (21 kDa) that inhibits cyclin-dependent kinases.
It is a key downstream target of p53 upon DNA damage and has multiple functions during cell cycle
regulation, DNA repair, gene transcription, and apoptosis [8]. We have previously discussed the link
between histone deacetylase inhibitors (HDACi) and p21cip1/waf1 signaling [9]. Here, we will extend
this discussion to epigenetic mechanisms, such as DNA or histone methylation, and their effects on
p21caip1/waf1 in cancer cells.
2. Epigenetic Mechanisms
2.1. Epigenetic Writers
The epigenetic landscape of tumor cells is created by various chemical modifications at DNA or
histone tails.
DNA methylation occurs in somatic cells at the so-called CpG (cytosine–phosphate–guanine)
islands, mostly CG-rich DNA sequences in the gene promoter regions and usually leads to silencing of
the respective gene. This modification is mediated by the DNA methyltransferase (DNMT) family [10].
In cancer, about 5–10% of promoter regions become abnormally methylated [11]. DNMT1 is considered
to be a maintenance DNA methyltransferase that copies methylation patterns during DNA replication
and is thus important to the inheritance of DNA methylation, while DNMT3a and DNMT3b act as
de novo DNA methyltransferases during embryogenesis and in somatic tissues [12,13]. Although
the promoter region of CDKN1A, the gene encoding p21cip1/waf1, is usually not methylated in acute
myeloid leukemia (AML), decitabine is capable of inducing its re-expression via induction of DNA
damage and activation of the ATM/p53 pathway [14].
Histone modifications make a major contribution to the transcriptional outcome of a specific gene
sequence. Interestingly, a histone lysine residue can be modified differentially; i.e., it can be acetylated
or (tri-)methylated, and each modification will contribute to cancer development in a different way
and extends the language of the DNA sequence [15,16]. Lysine acetyltransferases (KATs) catalyze the
transfer of an acetyl group from acetyl–CoA to the ε-amino group of a lysine. Histone acetylation
is a modification that can be recognized by epigenetic readers, but it also leads to a more relaxed
chromatin structure and, consequently, an enhanced binding of transcription factors. Acetylation can
occur at different histone tail lysines (K9, K14, K18, K5, K8, and K12) and in non-histone proteins.
TIP60 and GCN5 are further acetyltransferases that link epigenetic modifications to p21cip1/waf1, e.g.,
by acetylation of p53 and MYC, respectively [17–19].
H3K4 methylation in general marks a transcriptionally active gene. There are six
methyltransferases (MLL1/KMT2A, MLL2/KMT2B, MLL3/KMT2C, MLL4/KMT2D, SETD1A/KMT2F,
and SETD1B/KMT2G) that lead in different complexes to this active histone modification. Mutations
and rearrangements of the histone-lysine N-methyltransferase 2 (MLL) family proteins play a major
role in the initiation and maintenance of various cancer types [20]; p53 might be involved in the correct
recruitment of the Set1 complex to DNA-damage-responsive genes and thus links this phenotype to
p21cip1/waf1 [21]. The association of methyltransferases in diseases has recently been summarized in
Hyun et al. [22].
The H3K27me3 mark is associated with gene silencing. The responsible Polycomb repressive
complex 2 (PRC2) is composed of four core subunits: EZH2, SUZ12, EED, and RbAp46/48. The catalytic
subunit EZH2 is responsible for the mono-, di-, and trimethylation of lysine 27 on histone H3 [23].
EZH2 is upregulated in many cancers, and the inhibition of PRC2 catalytic activity has emerged as a
promising therapeutic approach in cancer [24,25].
There are at least eight different H3K36 methyltransferases; the most important are NSD1/KMT3B,
NSD2/KMT3G, NSD3/KMT3F, and SETD2/KMT3A [26].
Dot1L is responsible for the active mark at H3K79 that is localized at the globular domain of
histone 3. The relationship of the abovementioned epigenetic writers to p21cip1/waf1 is summarized in
Table 1 and discussed in further detail below.
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2.2. Epigenetic Erasers
Modifications to DNA and histones need to be reversible to be functional regulators of gene activity
and are performed by distinct enzymes that are classified as epigenetic erasers. Generally, the removal
of methylation marks facilitates transcription and enhances gene expression, while deacetylation has
suppressive effects.
DNA methylation can be reversed by the ten-eleven translocation (TET1-3) family of proteins [27].
TET proteins are DNA hydroxylases that convert 5-methylcytosine to 5-hydroxymethylcytosine
and, if the oxidization process is repeated, to 5-formylcytosine and 5-carboxylcytosine [28–30].
5-hydroxymethylcytosine is commonly found in sites of active chromatin, such as promoters and
transcriptional start sites, and it has been identified as a recognition signal for epigenetic readers [31,32].
Mutations in TET2 (leading to decreased 5-hydroxymethylcytosine levels) have been associated with
various hematologic malignancies [33], although the exact mechanism of how TET2 contributes to the
development of such cancers remains unclear [34]. Epigenetic inactivation or reduced expression of
TET3 has been demonstrated in solid tumors such as head and neck, cervical, or colon cancer [35–37].
Histone lysine demethylases (KDMs) consist of more than 30 enzymes that have a distinct
substrate specificity and belong to two different enzyme families: the Flavin-Adenin-Dinukleotid
(FAD)-dependent amine oxidase family with KDM1A and KDM1B (LSD1, LSD2) as the only two
members and the Jumonji C-domain-containing family of dioxygenases with more than 30 members
in several subfamilies (KDM2–8). KDM1A/B can remove mono- and dimethyl groups from histone
H3K4, while the Jumonji-family enzymes can also remove trimethyl groups [38,39]. So far, no clear
evidence for specific histone arginine demethylases exists. Peptidylarginine deiminase 4 (PAD4) and
JMJD6 have been shown to mediate arginine demethylation, but both enzymes also possess additional
properties beyond demethylation [40,41].
Histone deacetylation is removed by zinc-dependent Class I, II, and IV histone deacetylases
(HDAC) or Nicotinamide adenine dinucleotide + (NAD+)-dependent sirtuins that are also referred
to as Class III HDACs. HDACs remove ε-amino acetyl groups from lysine residues in histones
and in non-histone proteins (especially mediated by Class II HDACs, which are also found in the
cytoplasm), which explains the pleiotropic effects and rather narrow therapeutic window of HDAC
inhibitors (HDACi) in humans [42,43]. HDACs are part of larger multi-enzyme complexes, including
Sin3, NuRD, and Co-REST, that determine their target recognition and substrate specificity, but also
have demethylase properties [44,45]. Mechanistically, removal of acetylation from histones restores a
condensed and transcriptionally repressive status. While mutations in HDACs are uncommon, altered
expression levels of HDACs have been described in various human cancers and proposed as prognostic
markers, e.g., in colorectal, ovarian, breast, and liver cancer [46–49].
2.3. Epigenetic Readers
Epigenetic modifications are recognized by a group of proteins that are referred to as epigenetic
readers. Most reader proteins specifically recognize and interact with specific epigenetic marks;
however, some readers also bind to unmodified histones whose functional relevance is not well
understood yet [50–53].
Methylated CpG islands in DNA are recognized by methyl-CpG-binding proteins (MBPs),
and these proteins in general support the gene silencing properties of methylated loci. Three
families of MBPs have been described: MBD proteins (MBD1-6, SETDB1/2, BAZ2A/B, and MeCP2),
Zinc Finger (ZnF) domain proteins (ZBTB4, ZBTB33/Kaiso, ZBTB38, and ZFP57), and the SET and
RING finger-associated (SRA) domain proteins (UHRF1) [6,54].
Histone lysine methylation marks are recognized by a plethora of different protein families that
specifically interact with distinct lysine residues and their methylation pattern [55,56]. Interestingly,
a cross-talk between DNA and histone methylation exists by, e.g., interaction of the ATRX, DNMT3,
DNMT3L (ADD) domain of DNMT3 with the histone H3 or the binding of the DNA methylation
reader UHRF1 with unmethylated H3R2 [57–59].
Cancers 2019, 11, 1343 4 of 20
Acetylation of histones leads to an open chromatin structure that is recognized by proteins
containing bromodomains or tandem plant homeodomain (PHD) domains [60,61]. In humans,
more than 60 bromodomains have been identified [62]. Among them, the bromo- and extraterminal
domain (BET) family proteins (BRD2, BRD3, BRD4, and BRDT) are the best studied and have been
shown to regulate transcriptional elongation processes as well as cell cycle progression. Interestingly,
inhibition of BET proteins leads to downregulation of MYC, which is a key regulator of cellular survival
and proliferation (e.g., via p21cip1/waf1) in hematologic and solid tumors [63–65]. Other acetylation
readers, such as EP300 and CREBBP, possess only a single bromodomain and are also known to regulate
gene transcription processes [66].
3. Epigenetic Regulation of p21cip1/waf1
3.1. Promoter Methylation of CDKN1A
Expression of p21cip1/waf1 is regulated by several epigenetic and other additional
post-transcriptional mechanisms that are also interconnected with each other (Tables 1 and 2).
The proximal promoter of CDKN1A contains several CpG dinucleotides that can be subject to
DNA methylation [67,68]. Methylation affects Sp1 and Sp3 binding activity and was shown to suppress
p21cip1/waf1 transcription independently of p53 [69,70]. Some anticancer compounds, such as curcumin,
induce apoptosis by promoter demethylation of CDKN1A [68]. In prolactinoma, low p21cip1/waf1 levels
caused by CDKN1A promoter hypermethylation were shown to contribute to enhanced proliferation
in invasive specimens [71].
Hypermethylation of the Sp1 and Sp3 genomic region and concomitant transcriptional repression
were found in different hematologic and solid cancers, including breast cancer, and were associated
with a poorer prognosis due to more aggressive phenotypes [72–74]. DNMTs, as mediators of DNA
methylation, have thus also been shown to have elevated levels in cancer, and pharmacological
inhibition of these enzymes is already a clinical standard in hematologic diseases [75]. Furthermore,
DNMTs compete with p21cip1/waf1 for PCNA binding and overexpression of DNMTs could thus release
p21cip1/waf1 from PCNA and render it more susceptible to proteasomal degradation [76,77].
Nevertheless, low p21cip1/waf1 levels in tissues are not always associated with CDKN1A promoter
hypermethylation as previously shown in osteoarthritic chondrocytes [78].
Analyzing in silico the MethHC database that integrates DNA methylation and mRNA expression
data from the Cancer Genome Atlas (TCGA), we observed that there is no uniform pattern when
comparing tumor with nontumor DNA for CDKN1A gene expression. Bladder cancer, colon cancer,
liver hepatocellular carcinoma, and thyroid carcinoma show a lower CDKN1A expression in tumors,
whereas cervical squamous cell carcinoma, lung squamous carcinoma, prostate adenocarcinoma,
sarcoma, skin cutaneous carcinoma, and uterine corpus endometrial carcinoma show a higher
p21cip1/waf1 encoding mRNA expression in tumors compared to their normal counterparts (Figure 1).
Head and neck carcinoma did not even show different gene expression levels. Except for prostate
and skin carcinoma, there were no impressive differences visible to the naked eye in the graphs.
As expected, when analyzing DNA promoter methylation and CDKN1A gene expression, there was
a negative correlation between both parameters except for uterine corpus endometrial carcinoma;
however, the correlation coefficients were not remarkably high (Figure 2). These results point to the
fact that CDKN1A silencing is not epigenetically regulated by DNA methylation only. We summarize
the major mechanisms in the following paragraphs.
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Figure 1. Comparison of average CDKN1A gene expression in a tumor sample (Tu) and matched
normal samples (NT) in a panel of different tumor types. Data were taken from the MethHC database
(http://methhc.mbc.nctu.edu.tw/) for p21cip1/waf1 (NM-000389). * p < 0.05; ** p < 0.005.
Figure 2. Comparison of promoter DNA methylation level and mRNA expression in tumor samples in
a panel of different tumor types. ß values for methylation are between 0 and 1: 0—unmethylated and
1—fully methylated. Data were taken from the MethHC database (http://methhc.mbc.nctu.edu.tw/) for
p21cip1/waf1(Nm-000389). r, correlation coefficient.
3.2. Writers and p21cip1/waf1
Several histone acetyl transferases (HATs), e.g., p300, CREB-binding protein, PCAF, Tip60,
and GCN5, have been shown to be crucial for p53-dependent and independent activation of
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p21cip1/waf1 [79,80] (Table 1). Interestingly, the histone acetyltransferase PCAF can induce the acetylation
of H3K9 and H3K14 at the distal p53-responsive element in the CDKN1A promoter to induce its
expression under stress conditions. This action is independent of PCAF-mediated acetylation at K320
in p53’s regulatory domain [79,80]. The TIP60 protein is a lysine acetyltransferase that can directly
acetylate histones or non-histone proteins to alter their activity. TIP60 was shown to act as a tumor
suppressor in vivo. In human papilloma virus (HPV)-mediated cervical cancer, TIP60 is destabilized
by the HPV-mediated complex with the E3 ubiquitin ligase EDD1 [81]. High TIP60 expression was
associated with 5-Fluoruracil (5-FU)-induced apoptosis and growth arrest and is not restricted to
p53-dependent promoters [18]. The reason for this is that acetylation at the two TIP60-mediated
acetylation sites Lys161 and Lys163 at the p21cip1/waf1 C-terminus leads to stabilization of p21cip1/waf1
and this acetylation is a pre-requisite for p21cip1/waf1-dependent DNA damage response and cell
cycle progression.
Table 1. Overview of p21cip1/waf1 regulation by epigenetic writers.
Writers Epigenetic Mark ExperimentalConditions p21
cip1/waf1 Regulation Ref.
DNMTs 5mC Lung cancer cells 5mC affects Sp1 and Sp3binding activity [82]
TIP60 H2/H4ac Decreased in colon andbreast cancer
Acetylates the damage sensor
ATM or the gate keeper p53 [17,18]
PCAF H3K9/H3K14 Osteosarcoma andNSCLC cells Expression ↓ [83]
G9a-GLP H3K9me
Cervical cancer and
acute promyelocytic
leukemia cells
Recruited by Gfi1,
transcription ↓ [84]
CTIP2 H3K9me3 Microglial cells Induces transcriptionalrepression of p21 [85]
EZH2 H3K27me3 Erythroleukemia andNSCLC cells
Induces transcriptional
repression of p21 [86,87]
DOT1L H3K79 NSCLC
DOT1L inhibition reduces
H3K79me and increases p21
expression
[88]
PRMT6 H3R2me2 Prostate cancer PRMT6 silencing leads toincreased p21 expression [89]
Suv4-20h1 H4K20me Myeloid leukemia cells Induces transcriptionalrepression of p21 [90]
H2A.Z Osteosarcoma cells
Reduces binding of TIP60 to
p21 promotor and activates
p21 transcription
[91,92]
DNMTs—DNA methyltransferases; EZH2—enhancer of zeste homolog 2; G9a-GLP—G9a and G9a-like protein;
CTIP2—chicken ovalbumin upstream promoter transcription factor-interacting protein 2; DOT1L—disruptor of
telomeric silencing 1-like; PRMT6—protein arginine-N-methyltransferase; Suv4-20h1—suppressor of variegation
4-20 homolog 1; H2—histone H2; H4ac—histone H4 acetylation; H3K9/H3K14—histone H3 lysine 9/histone H3 lysine
14; H3K9me—histone H3 lysine 9 methylation; H3K9me3—histone H3 lysine 9 trimethylation; H3K79—histone
H3 lysine 79; H3R2me2—histone H3 arginine 2 dimethylation; H4K20me—histone H4 lysine 20 methylation;
H2A.Z—histone H2 A variant Z; NSCLC—non-small cell lung cancer; ATM—ataxia telangiectasia mutated.
SETD1A a histone methyltransferase that ensures that the active H3K4 methylation triggers cell
proliferation by suppressing p21cip1/waf1 in a p53-independent manner. On the other hand, SETD1A
knockdown leads to a p21cip1/waf1-dependent senescence phenotype [93]. The fact that SETD1A is
often amplified in invasive breast carcinomas might reflect the better tolerance of these aggressive
tumor cells to mitotic stress. Cell cycle arrest in SETD1A knockdown senescent cells is independent
of mutations in p53, Rb, and p16, which are known senescence mediators; instead, it is sustained
through transcriptional suppression of SKP2, which degrades p27 and p21cip1/waf1. The histone
methyltransferase SETD2, which is responsible for the trimethylation of H3K36, is necessary for the
proper mismatch repair in vivo [35]. In this regard, it has been shown that the hMutSα subunit of
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the mismatch repair protein hMSH6 contains a Pro–Trp–Trp–Pro (PWWP) domain that reads the
H3K36me3 histone mark [94]. SETD2 can interact with p53 to regulate the transcription of its target
genes encoding for e.g. p21cip1/waf1, Fas, and Puma [95]. SETD2 loss could also promote tumor growth
in a p53-independent manner, leading to aberrant mitosis and multinucleated giant cells in tumors.
In lymphoma, the growth factor independent 1 (Gfi1) oncoprotein mediates the recruitment
of the histone lysine methyltransferase G9a in complex with the histone deacetylase HDAC1 to
the CDKN1A promoter. The subsequent increase in H3K9 dimethylation leads to diminished
CDKN1A transcription [36]. Recently, the COUP-TF-interacting protein 2 (CTIP2) and the histone
methyltransferase SUV39H1 were shown to be recruited to the proximal SP1 site of the CDKN1A
promoter, and trimethylation of H3K9 was found to lead to transcriptional repression of CDKN1A in
microglial cells. In parallel, human immunodeficiency virus (HIV-1) infection of macrophages activates
CDKN1A gene expression and promotes G2/M cell cycle arrest. Both actions seem to facilitate HIV-1
replication [37].
Overexpressed MYC induces acute erythroleukemia, an uncommon AML subtype that is associated
with a worse prognosis. The histone methyltransferase EZH2 has been reported to be a target of the
MYC oncoprotein. MYC knockdown results in reduced EZH2 expression and an increase in p21cip1/waf1
expression by removal of the silencing EZH2-specific H3K27me3 mark at the CDKN1A promoter.
The subsequently induced p21cip1/waf1-dependent senescence phenotype is p53-independent [38].
In non-small-cell lung cancer, the long noncoding RNA LINCO1133 recruits EZH2 and lysine-specific
demethylase 1A (LSD1) to the CDKN1A promoter to repress its transcription, leading to a proliferative
stimulus [39]. Whereas EZH2 sets the silencing H3K27me3 mark, LSD1 removes the active H3K4me1/2
code to shape the chromatin into a repressive conformation. This p21cip1/waf1 suppression has also
been associated with epithelial-to-mesenchymal transition, a process that is important for invasion
and metastasis. Downregulation of methylation of H3K79 leads to a p21cip1/waf1-dependent induction
of the senescence program in lung cancer, which is believed to represent a barrier to tumorigenesis.
When tumor cells are deficient in the responsible methyltransferase DOT1, they show a remarkable
chromosomal instability [88]. When investigating a panel of histone methyltransferases in prostate
cancer, PRMT6, a Type I arginine methyltransferase that builds the H3R2 dimethylation, was highly
upregulated compared to nontumor tissue [89]. PRMT6 counteracts the MLL complex at H3K4 and
both marks are mutually exclusive. When the repressive H3R2me2 mark is lost, tumor aggressiveness
is significantly reduced by inhibition of the oncogenic AKT pathway and senescence induction via
p21cip1/waf1 upregulation. In leukemia, methylation at H4K20 by suppressor of variegation 4-20
homolog 1 (Suv4-20h1) promotes cell cycle G1/S transition and, hence, proliferation by repressing the
p21cip1/waf1 encoding gene [90]. A direct binding of Suv4-20h1 with enrichment of histones H3K20me2
and H4K20me3 at the CDKN1A promoter was shown in that study.
The histone variant H2A.Z is enriched at p53 binding sites in the CDKN1A promoter, facilitating
p53 binding and p21cip1/waf1 expression [91]. Interestingly, H2A.Z is lost from the CDKN1A promoter in
response to DNA damage followed by recruitment of TIP60 histone acetyltransferase to triggerCDKN1A
gene expression [92]. Thus, H2A.Z seems to be a negative regulator of p21cip1/waf1. The authors show
that p53 plays an active role in positioning H2A.Z to gene promoters and contributes to p21cip1/waf1
induction in an H2A.Z-depleted setting. In contrast, MYC represses CDKN1A transcription by
preferentially recruiting H2A.Z at MYC binding sites in the TATA initiator region of the CDKN1A
promoter to protect the malignant cells from senescence [91,92].
These findings indicate a tight and complex crosstalk between different epigenetic mechanisms in
regulating p21cip1/waf1 expression in different human cancer cells.
3.3. Erasers and p21cip1/waf1
Besides DNA methylation, histone H3 lysine methylation/demethylation was demonstrated
to regulate p21cip1/waf1 expression (Table 2). Lysine-specific demethylase (LSD1/KDM1A) is a key
regulator of histone H3K4 and H3K9 mono- and dimethylation [96]. It is commonly overexpressed and
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correlated with a poor prognosis in different human cancers [97–99]. LSD1 regulates p21cip1/waf1 [100]
via demethylation of histone and non-histone targets, including p53 and DNMT1 [101], and controls
the cell cycle via demethylation of Rb, interaction with long noncoding RNAs (lncRNAs) (including
HOTAIR), and demethylation of AGO2, a key element of the RNA-induced silencing complex [96,102].
In glioma and renal tumor cells, LSD1 knockdown enhanced CDKN1A transcription. This was
correlated with increased levels of H3K4me2 at the CDKN1A promotor [100,101] (Table 2). Surprisingly,
in prostate cancer, LSD1 knockdown resulted in increased H3K4me2 in the CDKN1A promotor,
but repressed CDKN1A transcription. However, LSD1 knockdown increased DNMT1 binding to the
promotor; thus, methylation might be responsible for the reduced levels of p21cip1/waf1 [103].
Table 2. Overview of p21cip1/waf1 regulation by epigenetic erasers.
Erasers Epigenetic Mark ExperimentalConditions p21
cip1/waf1 Regulation Ref.
TET 5hmC Glioma cells Expression ↑ [104]
KDM1A/LSD1 H3K4/H3K9me
Renal cells
carcinoma and
glioma
Regulates p21cip1/waf1 via
demethylation of histone and
non-histone targets
[100,101]
HDAC Histonedeacetylation
Multiple myeloma
and NSCLC Expression ↑ [105,106]
TET—ten-eleven translocation; KDM1A/LSD1—lysine-specific (histone) demethylase 1; HDAC—histone
deacetylases; 5hmC—5-hydroxymethylcytosine; H3K4/H3K9me—histone H3 lysine 4/histone H3 lysine 9
methylation; NSCLC—non-small cell lung cancer.
Mutations of isocitrate dehydrogenase (IDH) lead to the generation of 2-hydroxoglutarate (2-HG),
an oncometabolite, instead of the physiologic metaboliteα-ketoglutarate (α-KG), which is a co-substrate
for TET and Jumonji enzymes. 2-HG acts as a competitive inhibitor to these epigenetic modifiers and,
thus, increases histone lysine methylation and decreases 5-hydroxymethylcytosine levels [107], which
can lead to enhanced expression of p21cip1/waf1 [104]. Interestingly, IDH mutations are frequently
observed in glioblastoma, intrahepatic cholangiocellular carcinoma, and acute myeloid leukemia,
where epigenetic alterations are commonly found, and are already part of established diagnostic and
therapeutic algorithms [108–110].
It is known that vitamin C can increase the levels of TET enzymes [111,112]. In skin cancer cells,
this treatment induced a global DNA demethylation, which was associated with elevated 5hmC levels
in the CDKN1A promotor and increased p21cip1/waf1 expression. Knockout of the enzymes TET1/TET2
inhibited p21cip1/waf1 upregulation, suggesting that TET regulates p21cip1/waf1 expression in skin cancer
cells treated with vitamin C [113].
In agreement with our previous report [9], recent studies have continued to demonstrate the
regulation of p21cip1/waf1 expression by HDAC inhibitors (HDACi) in tumors. In non-small-cell
lung carcinoma, treatment with HDACi alone or in combination with the natural flavonolignan
silibinin caused increased H3 and H4 acetylation in the Sp1/Sp3 binding site at the CDKN1A promoter,
activating CDKN1A transcription [105]. In colorectal cancer cells, individual treatment with different
HDACi, such as Trichostatin A, SAHA, and sodium phenylbutyrate (NaPB), strongly increased
p21cip1/waf1 mRNA and protein levels. Specifically, the effect of NaPB, an inhibitor of predominantly
nuclear HDACs, on p21cip1/waf1 regulation was evaluated. Treatment increased H3K27ac occupancy
at the CDKN1A promotor and the enhancer region, demonstrating that p21cip1/waf1 expression is
regulated by histone acetylation [114]. In pancreatic cancer cells, SAHA induced increased expression
of p21cip1/waf1 levels as well as increased acetylation of histone H3 globally and specifically at the
CDKN1A promotor [115]. The same was observed in multiple myeloma cells treated with the novel
HDAC inhibitor Scriptaid [106]. Moreover, other studies have reported the modulation of p21cip1/waf1
expression after HDAC inhibition in lymphoma [116], leukemia [117], hepatocellular carcinoma [118],
and breast cancer [119]; however, histone marks were not investigated.
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4. The Role of lncRNAs and miRNAs in the Deregulation of p21cip1/waf1 in Cancer
Interestingly, long noncoding RNAs (lncRNA) have been shown to be involved in the regulation
of p21cip1/waf1 (Figure 3, Table 3). Overexpression of the long noncoding RNA HOXA cluster antisense
RNA2 (HOXA–AS2) is associated with tumor size, TNM stage, and a poor prognosis in gastric cancer.
Interestingly, this lncRNA promotes gastric cancer cell proliferation by downregulating mRNA levels
of CDKN1A in vitro and in vivo via binding with enhancer of zeste homolog 2 (EZH2) [102]. The long
noncoding RNA plasmacytoma variant translocation 1 (PVT1) is upregulated in pancreatic duct
adenocarcinoma (PDAC) tissues and has been shown to promote pancreatic cancer cell proliferation
and migration, and epithelial-to-mesenchymal transition (EMT), by downregulating p21cip1/waf1 [120].
The HOX Antisense Intergenic RNA (HOTAIR), which is overexpressed in a wide variety of cancers,
including cervical cancer, is able to silence p21cip1/waf1 and promote cancer radio-resistance in vitro and
in vivo [121]. Other long noncoding RNAs that have been shown to silence p21cip1/waf1 during human
malignancies include the antisense noncoding RNA in the INK4 locus (ANRIL), which is upregulated
in non-small-cell lung cancer tissues. Through silencing p21cip1/waf1 expression, ANRIL promotes
cancer cell proliferation and inhibits apoptosis. The mechanism of silencing includes binding to EZH2,
in addition to a direct binding to the p21cip1/waf1 promotor that mediates H3K27me3 modification [122].
Recently, the lncRNA MIR31HG was found to promote cell cycle progression and proliferation in
head and neck squamous cell carcinoma (HNSCC) by targeting p21cip1/waf1 [123]. The BRAF-activated
noncoding RNA (BANCR) interacts with p21cip1/waf1 and increases its expression to induce cell cycle
arrest and apoptosis in colorectal cancer [124].
Figure 3. Regulation of p21cip1/waf1 expression by noncoding RNAs (ncRNAs). (left figure)—
Mechanistic p21cip1/waf1 repression. Several microRNAs (miRNAs) and long noncoding RNAs
(lncRNAs) were shown to inhibit CDKN1A transcription by directly interacting with its promotor.
The expression of these ncRNAs in tumor cells led to p21cip1/waf1 repression. (right figure)—Mechanistic
p21cip1/waf1 activation. On the other hand, some miRNAs were shown to enhanceCDKN1A transcription
by remodeling histones or targeting putative sites in its promotor. The expression of these miRNAs
in cancer cells led to increased levels of p21cip1/waf1. Moreover, the BRAF-activated noncoding RNA
(BANCR) interacts with p21cip1/waf1 to increase its expression.
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MicroRNAs are small noncoding RNAs that are 18–25 nucleotides long [125]. They play an
important role in gene regulation at the post-transcriptional level by targeting mRNAs and inducing
their degradation and/or inhibiting their translation [125,126]. Notably, miRNAs can activate the
expression of specific genes by targeting their promotors [127,128]. miRNAs have been strongly
implicated in tumorigenesis and their deregulation is correlated with the hallmarks of cancer [129–131].
miR-125a and miR-125b have been shown to downregulate p53, thereby resulting in decreased
expression of p21 [131,132]. Several other miRNAs have been reported to directly downregulate
p21cip1/Waf1 by binding to its 3’-UTR, and these include miR-17, miR-20a, miR-20b, miR-93, miR-106a,
and miR-106b (reviewed by Jung et al. [133]). Subsequently, upregulation of these miRNAs promotes
cellular proliferation [133]. Conversely, let-7a targets Np95 ICBP90 ring finger (NIRF) and, therefore,
upregulates p21 expression; however, the mechanism by which NIRF regulates p21 remains elusive [129].
Recent studies show a complicated role of miRNAs in regulating p21cip1/waf1 in cancer cells (Figure 1,
Table 3). Plasma and tissue samples obtained from lung cancer patients showed an overexpression
of miR-93-5p and a reduced expression of p21cip1/waf1 and Bcl-w, indicating a potential role of this
miRNA in suppressing senescence through p21cip1/waf1 [130]. miR-208a has also been shown to be
overexpressed in the serum of lung cancer patients who were subjected to radiation therapy. A further
analysis indicated that this miRNA directly targets p21cip1/waf1 and affects the AKT/mTOR pathway to
promote cell proliferation and radio-resistance. miR-208a is predicted to bind to a putative binding
site at positions 86–92 in the 3’UTR of CDKN1A mRNA. Interestingly, this miRNA is secreted by lung
cancer cells in response to radiation. Moreover, it was shown that serum miR-208a can be taken up
by these cells via exosomes in a time-dependent manner [134]. A recent in vivo analysis of human
cervical cancer tissue showed an upregulation of miR-92a, which is associated with cervical cancer
progression. A complementary in vitro analysis revealed that p21cip1/waf1 is a direct target of miR-92a,
which promotes cell cycle progression through inhibiting p21cip1/waf1 expression in cervical cancer [135].
miR-17 5p has been reported to be upregulated in multi-drug resistant human gastric cancer cell
lines and its upregulation resulted in decreased expression of p21cip1/waf1 and drug resistance [136].
Evidence from a recent study has revealed a role of miR-95-3p in cell growth of osteosarcoma through
targeting of p21cip1/waf1. This miRNA has been also reported to be significantly upregulated in the
serum of osteosarcoma patients. The downregulation of this miRNA inhibited cell growth and induced
apoptosis by enhancing the activities of caspase-3 and caspase-9 and increasing the expression of
Bax/Bcl-2 proteins in osteosarcoma cells. On the other hand, the overexpression of miR-95-3p promoted
cell growth, while inhibiting apoptosis, by modulating TGF-β, cyclin D1, and p21cip1/waf1 expression
levels in these cells [137]. Similarly, miR-95-3p upregulation in a hepatocellular carcinoma (HCC) cell
line, HCC tissues, and HCC xenograft mouse models was found to promote tumor proliferation and
growth by directly targeting p21cip1/waf1. An in vitro analysis showed that the 15-bp region between
1500 bp and 1515 bp from the stop codon TAA at the 3′-UTR of CDKN1A contains the 3’UTR region that
is targeted by this miRNA [138]. An in vitro analysis has shown that miR-503-3p induces apoptosis
of lung cancer cells by downregulating p21cip1/waf1 and CDK4 expression [139]. miR-224 promotes
chemoresistance of in vitro and in vivo models of human lung adenocarcinoma through targeting
p21cip1/waf1 and thereby modulating G1/S transition and apoptosis [140].
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On the other hand, miR-3619-5p has been shown to activate p21cip1/waf1 expression by targeting
a putative site in its promotor. The same study showed that reduced expression of this miRNA
and p21cip1/waf1 is associated with cancer progression and poor survival of patients with bladder
carcinoma [141]. Another study showed that miR-370, miR-1180, and miR-1236 are downregulated
in bladder carcinoma tissues, and their overexpression led to p21cip1/waf1 activation and inhibition of
cancer. These miRNAs have been shown to induce the nuclear and not the cytoplasmic expression of
p21 by interacting directly with its promotor. As a result, CDK4/6 and cyclin D1, which are downstream
gene targets of p21cip1/waf1, were repressed following overexpression of the three miRNAs [142].
miR-6734 upregulates p21cip1/waf1 expression through modifying histones in the CDKN1A promoter
and induces cell cycle arrest in colon cancer cells. A detailed mechanistic analysis showed that this
miRNA directly interacts with the CDKN1A promotor by binding to a target site located at −360 to
−260 relative to the transcriptional start site [143]. Results from a recent study revealed that miR-200c
mediates sub-G1 and G2/M phase arrest and, consequently, enhances the radio-resistance of esophageal
squamous cancer cells through modulating the expression levels of several cell cycle regulators,
including p21cip1/waf1 [144]. The expression level of the lncRNA growth arrest specific transcript 5
(GAS5) has been observed to be downregulated in stomach cancer and resulted in decreased p21cip1/waf1
expression and impaired cell cycle arrest at the G1 phase. Importantly, the downregulation of GAS5
results in the downregulation of YBX1, a transactivator of p21cip1/waf1 in prostate cancer, thereby
decreasing p21cip1/waf1 expression [145].
All in all, these findings show a biological significance for the role of lncRNAs and miRNAs in the
deregulation of p21cip1/waf1 in cancer. However, the exact mechanism by which they affect the expression
levels of p21cip1/waf1 remains unclear and requires further investigation. Nevertheless, the use of these
noncoding RNAs as molecular biomarkers offers potential diagnostic and prognostic value for the better
management and treatment of cancer diseases associated with deregulated p21cip1/waf1 expression.
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Table 3. miRNAs and lncRNAs involved in the deregulation of p21 in cancer.
miRNA/LncRNA Cancer Type Expression Levels Biological Functions Ref.
HOXA cluster antisense RNA2
(HOXA-AS2) GC + Epigenetically silences p21 transcription and promotes cancer cell growth [102]
Plasmacytoma variant
translocation 1 (PVT1) PDAC +
Promotes cancer cell proliferation and migration, and epithelial-to-mesenchymal
transition (EMT), by downregulating p21 [120]
HOX Antisense Intergenic RNA
(HOTAIR) Cervix + Promotes radio-resistance by silencing p21 expression [121]
antisense noncoding RNA in the
INK4 locus (ANRIL) NSCLC +
Promotes cancer cell proliferation and inhibits apoptosis by silencing p21
expression [122]
LnCRNA MIR31HG HNSCC + Promotes cell cycle progression and proliferation by targeting p21 [123]
BRAF-activated noncoding
RNA (BANCR) CRC +
Interacts with p21 and increases its expression to induce cell cycle arrest and
apoptosis [124]
miR-93-5p Lung + in plasma and tissue samplesobtained from lung cancer patients Suppression of senescence through reducing the expression of p21 [130]
miR-208a Lung
+ in serum of lung cancer patients
who were subjected to radiation
therapy
Reduces the expression of p21 to promote cell proliferation and radio-resistance [134]
miR-92a Cervix + in human cervical tissues and Helacells
Promotes cell cycle progression and cell proliferation via inhibiting p21
expression [135]
miR-17-5p Multi-drug resistanthuman GC + Promotes drug resistance partially through downregulating p21 [136]
miR-95-3p OS, HCC + in the serum of OS patients and inan HCC cell line Promotes cell proliferation and growth by targeting p21
[137,
138]
miR-503-3p Lung cancer + Induces apoptosis of lung cancer cells by downregulating p21 and CDK4expression [139]
miR-224 Human lungadenocarcinoma
+ in cisplatin (DDP;
cis-diamminedichloroplatinum
II)-resistant A549 cells
Promotes chemo-resistance through targeting p21 and modulating G1/S
transition and apoptosis [140]
miR-3619-5p BC −
Activates p21 expression by targeting its putative promotor. Reduced expression
of this miRNA and p21 is associated with cancer progression and poor survival
of patients with BC
[141]
miR-370, miR-1180, and
miR-1236 BC – in BC tissues Activates p21 and inhibits cancer [142]
miR-6734 CC − Modifies histones in the p21 promoter and induces cell cycle arrest in coloncancer cells [143]
miR-200c ESCC −
Mediates sub-G1 and G2/M phase arrest and, consequently, enhances
radio-resistance of esophageal squamous cancer cells through modulating the
expression levels of several cell cycle regulators, including p21
[144]
lncRNA growth arrest specific
transcript 5 (GAS5) GC − Increases p21 expression and enhances cell cycle arrest at the G1 phase [145]
Note: Upregulation—(+); Downregulation—(–); GC—Gastric cancer; PDAC—pancreatic duct adenocarcinoma; NSCLC—non-small-cell lung cancer; HNSCC—head and neck squamous
cell carcinoma; CRC—colorectal cancer; OS—osteosarcoma; HCC—hepatocellular carcinoma; BC—bladder cancer; CC—colon cancer; ESCC—esophageal squamous cell carcinoma.
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5. Conclusions
In addition to the accumulation of multiple genetic alterations during the progression of cancer,
it is now widely established that global epigenetic changes also drive carcinogenesis as sequential
events. Aberrant epigenetic modifications lead to the expression or silencing of oncogenes and tumor
suppressor genes, respectively. The universal cyclin-dependent kinase CDK inhibitor p21, which
does not act as a transcription factor per se, is deregulated in many types of cancer. By showing dual
antagonism, it is involved in many hallmarks of cancer. The expression of p21 is largely mediated by
epigenetic modifications, such as DNA methylation, histone H3 methylation, and histone deacetylation.
Importantly, the deregulation of miRNAs and lncRNAs contributes to p21 repression or activation,
resulting in enhanced proliferation or growth arrest, drug response or resistance, and apoptosis or
survival, respectively. Given that epigenetic modifications are reversible, it is conceivable that the
epigenetic machinery, including noncoding RNAs, might be an important regulatory mechanism for
p21 in different stages of cancer or during various therapies. The use of epigenetic drugs, in combination
with conventional therapy, may lead to a novel approach for chemotherapy- and radiotherapy-resistant
cancers, and alterations in p21 should not be underestimated.
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